{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:10:42Z","timestamp":1779307842867,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clgc.2026.102534","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:54:15Z","timestamp":1773273255000},"page":"102534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Characteristics and Predictive Factors of Symptomatic Skeletal Events in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Denosumab"],"prefix":"10.1016","volume":"24","author":[{"given":"Yuzo","family":"Inaba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2599-8183","authenticated-orcid":false,"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juria","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhei","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7799-669X","authenticated-orcid":false,"given":"Keiichiro","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1044-912X","authenticated-orcid":false,"given":"Wataru","family":"Fukuokaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Iwatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4908-9444","authenticated-orcid":false,"given":"Mahito","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5673-1553","authenticated-orcid":false,"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102534_bib0001","unstructured":"Surveillance, Epidemiology, and End Results Program. Cancer stat facts: prostate cancer. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. Accessed: June 29, 2025."},{"issue":"4","key":"10.1016\/j.clgc.2026.102534_bib0002","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102534_bib0003","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/pcan.2011.7","article-title":"Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006","volume":"14","author":"Sathiakumar","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.clgc.2026.102534_bib0004","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1038\/s41598-020-63302-2","article-title":"Clinical aspects of mCRPC management in patients treated with radium-223","volume":"10","author":"Rizzini","year":"2020","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.clgc.2026.102534_bib0005","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"9768","key":"10.1016\/j.clgc.2026.102534_bib0006","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clgc.2026.102534_bib0007","first-page":"3395","article-title":"Ten-year experience of the multidisciplinary Osteoncology Center","volume":"27","author":"Bongiovanni","year":"2019","journal-title":"Support Care Cancer"},{"issue":"12","key":"10.1016\/j.clgc.2026.102534_bib0008","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102534_bib0009","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.critrevonc.2019.04.020","article-title":"The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone","volume":"139","author":"Hussain","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102534_bib0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.prnil.2024.11.003","article-title":"Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study","volume":"13","author":"Urabe","year":"2025","journal-title":"Prostate Int"},{"issue":"5","key":"10.1016\/j.clgc.2026.102534_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2025.02.007","article-title":"Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: real-world data from a multicenter study","volume":"43","author":"Urabe","year":"2025","journal-title":"Urol Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102534_bib0012","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/iju.15546","article-title":"Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: a multicenter study","volume":"31","author":"Urabe","year":"2024","journal-title":"Int J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102534_bib0013","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejca.2012.07.016","article-title":"Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis","volume":"49","author":"Ford","year":"2013","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2026.102534_bib0014","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/1097-0142(19880101)61:1<195::AID-CNCR2820610133>3.0.CO;2-Y","article-title":"Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan","volume":"61","author":"Soloway","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2026.102534_bib0015","article-title":"External validation and update of the risk prediction model for Denosumab-induced hypocalcemia developed from a hospital-based administrative database","volume":"8","author":"Ikegami","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"issue":"11","key":"10.1016\/j.clgc.2026.102534_bib0016","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102534_bib0017","unstructured":"National Comprehensive Cancer Network. Prostate cancer (Version 2.2025). Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed: June 29, 2025."},{"issue":"3","key":"10.1016\/j.clgc.2026.102534_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.2467","article-title":"Bone-modifying agents in patients with high-risk metastatic castration-sensitive prostate cancer treated with abiraterone acetate","volume":"7","author":"Fukuokaya","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.clgc.2026.102534_bib0019","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clgc.2021.10.008","article-title":"Symptomatic skeletal events and the use of bone health agents in a real-world treated metastatic castration resistant prostate cancer population: results from the CAPRI-study in the Netherlands","volume":"20","author":"Kuppen","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2026.102534_bib0020","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102534_bib0021","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.urology.2007.03.071","article-title":"Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer","volume":"70","author":"Smith","year":"2007","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.clgc.2026.102534_bib0022","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/1097-0142(20000715)89:2<363::AID-CNCR22>3.0.CO;2-3","article-title":"Predictors of skeletal complications in patients with metastatic breast carcinoma","volume":"89","author":"Domchek","year":"2000","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2026.102534_bib0023","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/JTO.0000000000000051","article-title":"Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13","volume":"9","author":"Katakami","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102534_bib0024","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1464-410X.2011.10192.x","article-title":"Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis","volume":"109","author":"Izumi","year":"2012","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.clgc.2026.102534_bib0025","first-page":"981","article-title":"Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate","volume":"30","author":"Miyashita","year":"2022","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2026.102534_bib0026","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13102818.2007.10817444","article-title":"Causes of high bone alkaline phosphatase","volume":"21","author":"Sara\u00e7","year":"2007","journal-title":"Biotechnol Biotechnol Equip"},{"issue":"5","key":"10.1016\/j.clgc.2026.102534_bib0027","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bju.16860","article-title":"Clinical features of medication-related osteonecrosis of the jaw in prostate cancer management","volume":"136","author":"Goto","year":"2025","journal-title":"BJU Int"},{"issue":"15 Suppl","key":"10.1016\/j.clgc.2026.102534_bib0028","doi-asserted-by":"crossref","first-page":"tps5095","DOI":"10.1200\/jco.2014.32.15_suppl.tps5095","article-title":"Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: a noninferiority phase III trial (SAKK 96\/12, REDUSE)","volume":"32","author":"Templeton","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102534_bib0029","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2020.08.019","article-title":"A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer","volume":"142","author":"Clemons","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2026.102534_bib0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:45:45Z","timestamp":1779306345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1558767326000340"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102534","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Characteristics and Predictive Factors of Symptomatic Skeletal Events in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Denosumab","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102534"}}